Biomedical products company Cerus posts rise in Q3 revenue; lifts 2025 guidance

Cerus

06/11/2025 21:29

Overview

Cerus Q3 total revenue up 19% yr/yr, driven by 15% product revenue growth

Adjusted EBITDA for Q3 beats analyst expectations

Company raises full-year 2025 product revenue guidance to $202 mln - $204 mln

Outlook

Cerus raises full-year 2025 product revenue guidance to $202 mln - $204 mln, from prior outlook of $200 mln-$203 mln

Company expects full-year 2025 IFC revenue between $16 mln and $17 mln

Result Drivers

IFC DEMAND - Increased U.S. hospital demand for INTERCEPT Fibrinogen Complex, supported by positive case studies from academic hospitals

GLOBAL EXECUTION - Strong global commercial execution and growing awareness of INTERCEPT Blood System benefits drove product revenue growth

GOVERNMENT CONTRACTS - Revenue increase from government contracts due to Phase 3 RedeS trial and pathogen reduction technology development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$20,000
Q3 Adjusted EBITDA
Beat
$5 mln
$2.87 mln (3 Analysts)
Q3 Gross Margin
53.40%
Q3 Gross Profit
$28.10 mln
Q3 Operating Expenses
$34.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Cerus Corp is $5.00, about 71% above its November 5 closing price of $1.45

Press Release: ID:nBwbYqdz2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)